Abstract Number: 685 • 2019 ACR/ARP Annual Meeting
Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus
Background/Purpose: Neutrophils play a crucial role in pathogenesis of systemic lupus erythematosus (SLE). Recently, neutrophil to lymphocyte ratio (NLR) has been studied as a biomarker…Abstract Number: 686 • 2019 ACR/ARP Annual Meeting
Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort
Background/Purpose: There is a lack of reliable biomarkers for disease activity in SLE. While C3a, an anaphylatoxin generated during of complement activation, could be predictive…Abstract Number: 687 • 2019 ACR/ARP Annual Meeting
CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are a hallmark of RA but are widely distributed in other autoimmune diseases. Although SLE is well characterized as…Abstract Number: 688 • 2019 ACR/ARP Annual Meeting
Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort
Background/Purpose: Diagnosis and classification of patients as having systemic lupus erythematosus (SLE) is critical in daily clinical practice as well as for clinical trials and…Abstract Number: 689 • 2019 ACR/ARP Annual Meeting
Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in…Abstract Number: 690 • 2019 ACR/ARP Annual Meeting
Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment
Background/Purpose: Monocytes/macrophages are the most abundant cells infiltrating the glomeruli and in the active urinary sediment of patients with Lupus Nephritis (LN).1 These cells also…Abstract Number: 691 • 2019 ACR/ARP Annual Meeting
Adjusted GAPSS in Systemic Lupus Erythematosus Patients in Argentina
Background/Purpose: Assessment of risk both for pregnancy morbidity and thrombosis in the presence of anti-phospholipid antibodies (aPL) is still a challenge. The Global Antiphospholipid Syndrome…Abstract Number: 692 • 2019 ACR/ARP Annual Meeting
Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker
Background/Purpose: Lupus nephritis (LN), is seen in 30-50% patients with SLE and 5-10% patients progress to end-stage renal disease. The clinical disease activity indices do…Abstract Number: 693 • 2019 ACR/ARP Annual Meeting
Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease of unknown etiology. Previous studies of beauty products as potential triggers of SLE development…Abstract Number: 694 • 2019 ACR/ARP Annual Meeting
Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE
Background/Purpose: Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and…Abstract Number: 695 • 2019 ACR/ARP Annual Meeting
Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis
Background/Purpose: Understanding the role of environmental exposures in the development of SLE and their association with SLE activity may help identify modifiable risk factors and…Abstract Number: 696 • 2019 ACR/ARP Annual Meeting
The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy
Background/Purpose: Lupus nephritis (LN) is associated with high morbidity and mortality. Current standard tools to monitor LN are suboptimal compared to the invasive renal biopsy.…Abstract Number: 697 • 2019 ACR/ARP Annual Meeting
Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients
Background/Purpose: Although SLE disproportionately affects minority racial groups, this population is significantly under-represented in clinical trials, increasing risk for underpowered, incorrect conclusions in race-based sub-group…Abstract Number: 698 • 2019 ACR/ARP Annual Meeting
Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus
Background/Purpose: Gene expression studies have previously demonstrated increased Type I interferon α (IFN) inducible genes in peripheral blood mononuclear cells of systemic lupus erythematosus (SLE)…Abstract Number: 699 • 2019 ACR/ARP Annual Meeting
Revising the SLEDAI-2K to Include Additional Constitutional Symptoms to More Accurately Assess Lupus Disease Activity
Background/Purpose: The SLEDAI-2K, a widely-used measure for disease activity, does not incorporate symptoms such as weight loss, lymphadenopathy (LAD) or fatigue which may limit accurate assessment…
ACR Meeting Abstracts